nach oben

Child's Nervous System

Erschienen in:

02.07.2020 | Focus Session

Adamantinomatous craniopharyngioma: advances in proteomic research

verfasst von: Claudia Desiderio, Diana Valeria Rossetti, Massimo Castagnola, Luca Massimi, Gianpiero Tamburrini

Erschienen in: Child's Nervous System | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Many efforts have been performed in the last decade to accomplish the genomic and proteomic characterization of pediatric adamantinomatous craniopharyngioma with the purpose to elucidate the molecular mechanisms underlying the onset and development of this pediatric brain tumor, its high recurrence rate, and, although classified as a histologically benign neoplasm, its aggressive behavior.

Methods

The focus of this review is to perform the new comparison of the proteomic profiles of the solid component and the intracystic fluid of adamantinomatous craniopharyngioma based on our previous results, obtained by both the top-down and the bottom-up proteomic approaches, to disclose differences and similarities, and to discuss the results in the context of the most recent literature.

Results and conclusions

Proteins and peptides identified in the cyst fluid and in the solid component of adamantinomatous craniopharyngioma (AC) include beyond markers of inflammation (i.e., alpha-defensins), proteins involved in cell migration and protein degradation (i.e., beta-thymosin and ubiquitin peptides), whose main role might be in tumor growth and infiltration of the surrounding neural structures. These last appeared different in the solid components compared with the cyst fluid, missing their terminal part in the solid tissue, a feature generally associated to malignancies, which might represent a distinct molecular site for an aggressive behavior of AC.

Massimi L, Martelli C, Caldarelli M, Castagnola M, Desiderio C (2017) Proteomics in pediatric cystic craniopharyngioma. Brain Pathol 27:370–376PubMed

Hengartner AC, Prince E, Vijmasi T Hankinson TC (2020) Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurg Focus 48:E7

Whelan R, Prince E, Gilani A, Hankinson T (2020) The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment. J Clin Med 9:519PubMedCentral

Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters B, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC, Advancing Treatment for Pediatric Craniopharyngioma Consortium (2017) Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol 76:779–788PubMedPubMedCentral

Iavarone F, Desiderio C, Vitali A, Messana I, Martelli C, Castagnola M, Cabras T (2018) Cryptides: latent peptides everywhere. Crit Rev Biochem Mol Biol 53:246–263PubMed

Pettorini BL, Inzitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, Cabras T, Messana I, Castagnola M, Di Rocco C (2010) The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst 26:1779–1784PubMed

Desiderio C, Martelli C, Rossetti DV, Di Rocco C, D’Angelo L, Caldarelli M, Tamburrini G, Iavarone F, Castagnola M, Messana I, Cabras T, Faa G (2013) Identification of thymosins β4 and β 10 in paediatric craniopharyngioma cystic fluid. Childs Nerv Syst 29:951–960PubMed

Martelli C, Iavarone F, Vincenzoni F, Rossetti DV, D’Angelo L, Tamburrini G, Caldarelli M, Di Rocco C, Messana I, Castagnola M, Desiderio C (2014) Proteomic characterization of pediatric craniopharyngioma intracystic fluid by LC-MS top-down/bottom-up integrated approaches. Electrophoresis 35:2172–2183PubMed

Martelli C, Serra R, Inserra I, Rossetti DV, Iavarone F, Vincenzoni F, Castagnola M, Urbani A, Tamburrini G, Caldarelli M, Massimi L, Desiderio C (2019) Investigating the protein signature of adamantinomatous craniopharyngioma pediatric brain tumor tissue: towards the comprehension of its aggressive behavior. Dis Markers 2;2019:3609789 https://doi.org/10.1155/2019/3609789

10.

Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Strojan P, Suárez C, Genden EM, Rinaldo A, Ferlito A (2012) Craniopharyngioma: a pathologic, clinical, and surgical review. Head Neck 34:1036–1044PubMed

11.

Maneerat Y, Prasongsukarn K, Benjathummarak S, Dechkhajorn W, Chaisri U (2016) Increased alpha-defensin expression is associated with risk of coronary heart disease: a feasible predictive inflammatory biomarker of coronary heart disease in hyperlipidemia patients. Lipids Health Dis 15:117PubMedPubMedCentral

12.

Ramasundara M, Leach ST, Lemberg DA, Day AS (2009) Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24:202–208PubMed

13.

Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS, van ‘t Wout EF, Dean JL, Gray NK, Lu W, Gray M (2016) Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation. Proc Natl Acad Sci U S A 113:4350–4355PubMedPubMedCentral

14.

Hannappel E (2007) Beta-thymosins. Ann N Y Acad Sci 1112:21–37

15.

Goldstein AL, Badamchian M (2004) Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther 4:559–573PubMed

16.

Pardon MC (2018) Anti-inflammatory potential of thymosin β4 in the central nervous system: implications for progressive neurodegenerative diseases. Expert Opin Biol Ther 18(sup1):165–169PubMed

17.

Crockford D, Turjman N, Allan C, Angel J (2010) Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 1194:179–189PubMed

18.

Sanders MC, Goldstein AL, Wang YL (1992) Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci U S A 89:4678–4682PubMedPubMedCentral

19.

Qiu P, Wheater MK, Qiu Y, Sosne G (2011) Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J 25:1815–1826PubMedPubMedCentral

20.

Nemolato S, Restivo A, Cabras T, Coni P, Zorcolo L, Orrù G, Fanari M, Cau F, Gerosa C, Fanni D, Messana I, Castagnola M, Casula G, Faa G (2012) Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. Cancer Biol Ther 13:191–197PubMed

21.

Yu FX, Lin SC, Morrison-Bogorad M, Yin HL (1994) Effects of thymosin beta 4 and thymosin beta 10 on actin structures in living cells. Cell Motil Cytoskeleton 27:13–25PubMed

22.

Kuzan A (2016) Thymosin β as an actin-binding protein with a variety of functions. Adv Clin Exp Med 25:1331–1336PubMed

23.

Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q (2005) Roles of thymosins in cancers and other organ systems. World J Surg 29:264–270PubMed

24.

Goldstein AL (2003) Thymosin beta4: a new molecular target for antitumor strategies. J Natl Cancer Inst 95:1646–1647PubMed

25.

Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C (2009) Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Investig 27:1016–1022

26.

Xiao Y, Chen Y, Wen J, Yan W, Zhou K, Cai W (2012) Thymosin β4: a potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr 22:109–116PubMed

27.

Cha HJ, Jeong MJ, Kleinman HK (2003) Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95:1674–1680PubMed

28.

Zhang Y, Feurino LW, Zhai Q, Wang H, Fisher WE, Chen C, Yao Q, Li M (2008) Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther 7:419–423PubMed

29.

Oh SY, Song JH, Gil JE, Kim JH, Yeom YI, Moon EY (2006) ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp Cell Res 312:1651–1657PubMed

30.

Gemoll T, Strohkamp S, Schillo K, Thorns C, Habermann JK (2015) MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer. Oncotarget 6:43869–43880PubMedPubMedCentral

31.

Theunissen W, Fanni D, Nemolato S, Di Felice E, Cabras T, Gerosa C, Van Eyken P, Messana I, Castagnola M, Faa G (2014) Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. Eur J Histochem 58:2242PubMedPubMedCentral

32.

Zhang X, Ren D, Guo L, Wang L, Wu S, Lin C, Ye L, Zhu J, Li J, Song L, Lin H, He Z (2017) Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast Cancer Res 19:15PubMedPubMedCentral

33.

Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, Tabatabai G (2014) Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 137(Pt 2):433–448

34.

Lee JW, Kim HS, Moon EY (2019) Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells. Sci Rep 9:6849PubMedPubMedCentral

35.

Martelli C, Iavarone F, D’Angelo L, Arba M, Vincenzoni F, Inserra I, Delfino D, Rossetti DV, Caretto M, Massimi L, Tamburrini G, Di Rocco C, Caldarelli M, Messana I, Castagnola M, Sanna MT, Desiderio C (2015) Integrated proteomic platforms for the comparative characterization of medulloblastoma and pilocytic astrocytoma pediatric brain tumors: a preliminary study. Mol BioSyst 11:1668–1683PubMed

36.

Rossetti DV, Massimi L, Martelli C, Vincenzoni F, Di Silvestre S, Scorpio G, Tamburrini G, Caldarelli M, Urbani A, Desiderio C (2020) Ependymoma pediatric brain tumor protein fingerprinting by integrated mass spectrometry platforms: a pilot investigation. Cancers (Basel) 12:674

37.

Delfino D, Rossetti DV, Martelli C, Inserra I, Vincenzoni F, Castagnola M, Urbani A, Scarpa S, Fuso A, Cavallaro RA, Desiderio C (2019) Exploring the brain tissue proteome of TgCRND8 Alzheimer’s disease model mice under B vitamin deficient diet induced hyperhomocysteinemia by LC-MS top-down platform. J Chromatogr B Analyt Technol Biomed Life Sci 1124:165–172PubMed

38.

Cabras T, Iavarone F, Martelli C, Delfino D, Rossetti DV, Inserra I, Manconi B, Desiderio C, Messana I, Hannappel E, Faa G, Castagnola M (2015) High-resolution mass spectrometry for thymosins detection and characterization. Expert Opin Biol Ther 15:S191–S201PubMed

39.

Heintz D, Reichert A, Mihelic-Rapp M, Stoeva S, Voelter W, Faulstich H (1994) The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin. Eur J Biochem 223:345–350PubMed

40.

Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD (1999) Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 5:1424–1427PubMed

41.

Evans MA, Smart N, Dubé KN, Bollini S, Clark JE, Evans HG, Taams LS, Richardson R, Lévesque M, Martin P, Mills K, Riegler J, Price AN, Lythgoe MF, Riley PR (2013) Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nat Commun 4:2081PubMedPubMedCentral

42.

Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM (2011) Protein signatures for survival and recurrence in metastatic melanoma. J Proteome 74:1002–1014

43.

Hegedus CM, Gunn L, Skibola CF, Zhang L, Shiao R, Fu S, Dalmasso EA, Metayer C, Dahl GV, Buffler PA, Smith MT (2005) Proteomic analysis of childhood leukemia. Leukemia 19:1713–1718PubMed

44.

Gonçalves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron Y, Esterni B, Monville F, Tarpin C, Jacquemier J, Houvenaeghel G, Chabannon C, Extra JM, Viens P, Borg JP, Birnbaum D (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420–1433PubMedPubMedCentral

45.

Laouirem S, Le Faouder J, Alexandrov T, Mestivier D, Léger T, Baudin X, Mebarki M, Paradis V, Camadro JM, Bedossa P (2014) Progression from cirrhosis to cancer is associated with early ubiquitin post-translational modifications: identification of new biomarkers of cirrhosis at risk of malignancy. J Pathol 234:452–463PubMed

46.

Desiderio C, D’Angelo L, Rossetti DV, Iavarone F, Giardina B, Castagnola M, Massimi L, Tamburrini G, Di Rocco C (2012) Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics 12:2158–2166PubMed

47.

Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ, Selle H (2010) Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 36:201–207PubMed

48.

Ziegler ME, Chen T, LeBlanc JF, Wei X, Gjertson DW, Li KC, Khalighi MA, Lassman CR, Veale JL, Gritsch HA, Reed EF (2011) Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection. Transplantation 92:388–395PubMed

49.

Pimenta DC, Chen VC, Chao J, Juliano MA, Juliano L (2000) Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D. J Protein Chem 19:411–418PubMed

Titel: Adamantinomatous craniopharyngioma: advances in proteomic research
verfasst von: Claudia Desiderio
Diana Valeria Rossetti
Massimo Castagnola
Luca Massimi
Gianpiero Tamburrini
Publikationsdatum: 02.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Child's Nervous System / Ausgabe 3/2021
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-020-04750-z

Neu im Fachgebiet Chirurgie

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results and conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Circulating glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 as markers of neuronal damage in children with epileptic seizures

Spinal intravascular papillary endothelial hyperplasia in an infant

Infected congenital lumbosacral dermal sinus tract with conus epidermoid abscess: a rare entity

Genome-wide association study across pediatric central nervous system tumors implicates shared predisposition and points to 1q25.2 (PAPPA2) and 11p12 (LRRC4C) as novel candidate susceptibility loci

Correction to: Discovering proteomics in pediatric brain tumors

Primary intracranial Ewing sarcoma/ peripheral primitive neuroectodermal tumor, an entity of unacquaintance: a series of 8 cases

Update Chirurgie